

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 December 2007 (13.12.2007)

PCT

(10) International Publication Number
WO 2007/143209 A2

(51) International Patent Classification:
A61K 31/69 (2006.01)

(21) International Application Number:
PCT/US2007/013211

(22) International Filing Date: 4 June 2007 (04.06.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/810,593 2 June 2006 (02.06.2006) US
60/842,237 5 September 2006 (05.09.2006) US
60/903,020 23 February 2007 (23.02.2007) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF VIRGINIA PATENT FOUNDATION** [US/US]; 250 West Main Street, Suite 300, Charlottesville, VA 22902 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FRASER, Cassandra, L.** [US/US]; 2404 Jefferson Park Avenue, Charlottesville, VA 22903 (US). **ZHANG, Guoqing** [CN/US]; 268 Colonnade Drive, Apt. 10, Charlottesville, VA 22903 (US). **CHEN, Jianbin** [CN/CN]; Rm. 807, 10 Hongxiang 2nd St. N., Caihong Rd., Foshan (CN).

(74) Agent: **PROUT, William, F.**; IPLM Group, P.A., Post Office Box 18455, Minneapolis, MN 55418 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: LUMINESCENT DIKETONATE POLYMERS



(57) Abstract: The present invention provides in one aspect polymeric luminescent dye compounds having fluorescent properties, phosphorescent properties, or both fluorescent and phosphorescent properties.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

198-P-01260WO01

LUMINESCENT DIKETONATE POLYMERS

5

Government Funding

[0001] This invention was made with United States Government support under Grant No. CHE-0350121 awarded by the National Science Foundation. The United States Government has certain rights in this invention..

10

Priority

[0002] This application claims the benefit of U.S. Provisional Application Numbers 60/810,593, filed June 2, 2006 60/842,237, filed September 5, 2006 and 60/903,020, filed February 23, 2007 the disclosures of which are incorporated by reference.

Background

15

[0003] There are many of optical oxygen sensing systems based on Ru, Pt, or Ir heavy metal luminophores. However, oxygen sensors based on non-heavy metal luminophores with unusual dual emissive properties (*e.g.*, based on boron), particularly single component systems with biocompatible “green” polymers are very rare. Fluorescent boron difluoride dyes such as “bodipy” and boron diketonates possess large molar extinction coefficients and two-photon
20 absorption cross sections, high emission quantum yields and sensitivity to the surrounding medium. These features have been exploited in lasers, imaging agents, molecular probes, and photosensitizers. As two-photon absorbers, they are compatible with optical imaging technologies employing tunable Ti:sapphire lasers (700-1100 nm). Focused, longer wavelength IR excitation corresponds with greater tissue penetration, and reduced cell damage
25 and interference from biological absorbers. Boron difluoride diketonate dyes possess large

dipole moments and their emission wavelength sensitive to the polarity of the surrounding medium. Thus, solvatochromic boron complexes serve as probes of their local environments.


[0004] A typical dual emissive system works as described below. Though boron dye fluorescence is well known, phosphorescence is usually only observed in the presence of toxic heavy atom substituents or additives (*e.g.*, Pb, Tl, or halogens such as I, Br), at low temperatures, or in rigid, solid matrices, which can be difficult to process and often are not biocompatible and biodegradable. Phosphorescence is quenched by oxygen, which at room temperature more accurately and conveniently may serve as the basis for quantitative optical oxygen sensing. Single component, readily processable systems exhibiting both fluorescence and phosphorescence are rare and may be adapted for imaging and ratiometric sensing. Fluorescence (short emission lifetimes) serves as an invariant feature providing information to quantify and locate the dye/emitter, whereas phosphorescence (long emission lifetimes) is quenched to variable extents depending upon the amount of oxygen that is present.

Phosphorescent materials with long emission lifetimes are more sensitive to oxygen, and may serve as highly sensitive oxygen sensors in low oxygen environments (food packaging, hypoxic tumor or cardiovascular tissues, tissue engineering matrices, etc.) Luminescent materials can also be used as photosensitizers, transferring energy to other molecules, and generating reactive species by light activation. For example, this feature is exploited in photodynamic therapy, generating reactive singlet oxygen to selectively damage tumor tissue, and in lithography with two-photon dyes.

[0005] Currently, there is a need for compounds that have the ability to both fluoresce and phosphoresce. There is also a need for sensors that can be used to detect oxygen at low levels in tumors and cardiovascular tissue.

Summary

[0006] The present invention provides in one aspect polymeric luminescent dye compounds having fluorescent properties, phosphorescent properties, or both fluorescent and phosphorescent properties. Accordingly, the invention provides compounds having formula I:




I

wherein R^1 and R^2 are independently (C_6-C_{22}) aryl or (C_5-C_{21}) heteroaryl. The R^1 and R^2 groups are optionally independently substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 substituent groups; where the substituent groups are halo, (C_1-C_{12}) alkyl, hydroxy (C_1-C_{12}) alkyl, halo (C_1-C_{12}) alkyl, $R^{15}O(C_1-C_{12})$ alkyl, $R^{15}O(C_1-C_{12})$ alkyl-O-, (C_2-C_{12}) alkenyl, (C_7-C_{26}) aralkyl, (C_5-C_{13}) heteroaryl, $-OR^{15}$, oxo ($>C=O$), $-CN$, $-NO_2$, $-CO_2R^{15}$, $-OC(O)R^{16}$, $-C(O)R^{16}$, $-NR^{13}R^{14}$, $-N(R^{23})C(O)R^{24}$, $-C(O)NR^{17}R^{18}$, $-SR^{19}$, $-SO_2R^{20}$, $-OSiR^{25}_3$, $-SiR^{25}_3-SiR^{25}_i(OR^{25})_j$, $-P(OR^{25})_3$, $-PR^{25}_3$, isocyanate, isothiocyanate, urea, or thiourea; or two substituent groups can form a ring together with the atom to which they are attached optionally having from 3 to 8 ring atoms and optionally having 1, 2, or 3 heteroatoms; each R^{25} is independently hydrogen, alkyl or aryl; and the sum of i and j is 3;

Y^1 is Al or B; X^1 and X^2 are independently a bond, alkyl, alkenyl, alkynyl or aryl, optionally substituted with 1, 2, 3, 4, 5, or 6 substituent groups; where the substituent groups are halo, (C_1-C_{12}) alkyl, hydroxy (C_1-C_{12}) alkyl, halo (C_1-C_{12}) alkyl, $R^{15}O(C_1-C_{12})$ alkyl, $R^{15}O(C_1-C_{12})$ alkyl-O-, (C_2-C_{12}) alkenyl, (C_7-C_{26}) aralkyl, (C_5-C_{13}) heteroaryl, $-OR^{15}$, oxo ($>C=O$), $-CN$, $-NO_2$, $-CO_2R^{15}$, $-OC(O)R^{16}$, $-C(O)R^{16}$, $-NR^{13}R^{14}$, $-N(R^{23})C(O)R^{24}$, $-C(O)NR^{17}R^{18}$, $-SR^{19}$, $-SO_2R^{20}$, $-OSiR_3$, $-SiR_3$, $-SiR^{25}_i(OR^{25})_j$, $-PR_3$, $-P(OR)_3$, isocyanate, isothiocyanate, urea, thiourea or two substituent groups can form a ring together with the atom to which they are attached optionally having from 3 to 8 ring atoms and optionally having 1, 2, or 3 heteroatoms;


R^3 and R^4 are independently, halo, hydroxy, $R^{15}O(C_1-C_{12})$ alkyl, $R^{15}O(C_1-C_{12})$ alkyl, or $-OR^{15}$; or R^3 and R^4 taken together form a bidentate chelate, such as deprotonated acid or diacid group, $HOC(=O)CH_2C(=O)OH$ (malonic acid) or $HOC(=O)CH_2C(=O)OH$ (oxalic

acid), or chelating group such as acid-alcohol, acid-ether, with two donor groups, or R³ and R⁴ taken together with the boron atom form a ring having the formula:



R⁵ is hydrogen, halo, (C₁-C₁₂)alkyl, hydroxy(C₁-C₁₂)alkyl, halo(C₁-C₁₂)alkyl, (C₂-C₁₂)alkenyl, (C₇-C₂₆)aralkyl, (C₅-C₁₃)heteroaryl, -OR¹⁵, -CN, -NO₂, -CO₂R¹⁵, -OC(O)R¹⁶, -C(O)R¹⁶, -NR¹³R¹⁴, -N(R²³)C(O)R²⁴, -C(O)NR¹⁷R¹⁸, -SR¹⁹, -SO₂R²⁰ or -SO₃H; or wherein R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²³ and R²⁴ are independently hydrogen, alkyl, alkenyl, (C₃-C₁₂)cycloalkyl, aryl, aralkyl or haloalkyl; each Q is a polymer chain where each chain is conjugated directly to the compound (e.g., via a covalent, coordinate, ionic, or hydrogen bond) through one of R¹, R², R⁵, X¹, X² or to a substituent attached to R¹, R², R⁵, X¹, or X²; and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, or 15; or a pharmaceutically acceptable salt thereof.

[0007] In another aspect the invention provides luminescent dye compositions having a polymer in combination with a luminescent dye compound formula II:



II


wherein the composition has fluorescent properties, phosphorescent properties, or both fluorescent and phosphorescent properties. In the luminescent dye compounds R¹ and R² are independently (C₆-C₂₂)aryl or (C₅-C₂₁)heteroaryl. The R¹ and R² groups are optionally independently substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 substituent groups; where the substituent groups are halo, (C₁-C₁₂)alkyl, hydroxy(C₁-C₁₂)alkyl, halo(C₁-C₁₂)alkyl, R¹⁵O(C₁-C₁₂)alkyl, R¹⁵O(C₁-C₁₂)alkyl-O-, (C₂-C₁₂)alkenyl, (C₇-C₂₆)aralkyl, (C₅-C₁₃)heteroaryl, -OR¹⁵, oxo (>C=O), -CN, -NO₂, -CO₂R¹⁵, -OC(O)R¹⁶, -C(O)R¹⁶, -NR¹³R¹⁴, -N(R²³)C(O)R²⁴, -C(O)NR¹⁷R¹⁸, -SR¹⁹, -SO₂R²⁰, -OSiR²⁵₃, -SiR²⁵₃, -SiR²⁵_i(OR²⁵)_j-, -P(OR²⁵)₃, -PR²⁵₃, isocyanate, isothiocyanate, urea, or thiourea; or two substituent groups can form a ring

together with the atom to which they are attached optionally having from 3 to 8 ring atoms and optionally having 1, 2, or 3 heteroatoms; each R^{25} is independently hydrogen, alkyl or aryl; and the sum of i and j is 3;

Y^1 is Al or B; X^1 and X^2 are independently a bond, alkyl, alkenyl, alkynyl or aryl,

- 5 optionally substituted with 1, 2, 3, 4, 5, or 6 substituent groups; where the substituent groups are halo, (C_1-C_{12}) alkyl, hydroxy (C_1-C_{12}) alkyl, halo (C_1-C_{12}) alkyl, $R^{15}O(C_1-C_{12})$ alkyl, $R^{15}O(C_1-C_{12})$ alkyl-O-, (C_2-C_{12}) alkenyl, (C_7-C_{26}) aralkyl, (C_5-C_{13}) heteroaryl, $-OR^{15}$, oxo ($>C=O$), $-CN$, $-NO_2$, $-CO_2R^{15}$, $-OC(O)R^{16}$, $-C(O)R^{16}$, $-NR^{13}R^{14}$, $-N(R^{23})C(O)R^{24}$, $-C(O)NR^{17}R^{18}$, $-SR^{19}$, $-SO_2R^{20}$, $-OSiR^{25}_3$, $-SiR^{25}_3$, $-SiR^{25}_i(OR^{25})_j$, $-P(OR^{25})_3$, $-PR^{25}_3$, isocyanate, isothiocyanate, 10 urea, or thiourea; or two substituent groups can form a ring together with the atom to which they are attached optionally having from 3 to 8 ring atoms and optionally having 1, 2, or 3 heteroatoms; each R^{25} is independently hydrogen, alkyl or aryl and the sum of i and j is 3;

- R^3 and R^4 are independently, halo, hydroxy, $R^{15}O(C_1-C_{12})$ alkyl, $R^{15}O(C_1-C_{12})$ alkyl, or $-OR^{15}$; or R^3 and R^4 taken together form a bidentate chelate, such as deprotonated acid or 15 diacid group, $HOC(=O)CH_2C(=O)OH$ (malonic acid) or $HOC(=O)CH_2C(=O)OH$ (oxalic acid), or chelating group such as acid-alcohol, acid-ether, with two donor groups, or R^3 and R^4 taken together with the boron atom form a ring having the formula:



- R^5 is hydrogen, halo, (C_1-C_{12}) alkyl, hydroxy (C_1-C_{12}) alkyl, halo (C_1-C_{12}) alkyl, (C_2-C_{12}) alkenyl, (C_7-C_{26}) aralkyl, (C_5-C_{13}) heteroaryl, $-OR^{15}$, $-CN$, $-NO_2$, $-CO_2R^{15}$, $-OC(O)R^{16}$, $-C(O)R^{16}$, $-NR^{13}R^{14}$, $-N(R^{23})C(O)R^{24}$, $-C(O)NR^{17}R^{18}$, $-SR^{19}$, $-SO_2R^{20}$ or $-SO_3H$; or wherein 20 R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{23} and R^{24} are independently hydrogen, alkyl, alkenyl, (C_3-C_{12}) cycloalkyl, aryl, aralkyl or haloalkyl; or a pharmaceutically acceptable salt thereof.

- [0008]** In another aspect the invention provides luminescent dyes that are color tunable, 25 e.g., the color from the fluorescence or phosphorescence of the luminescent dye may be altered by changing the groups, e.g., R^1 , R^2 , R^5 , X^1 and X^2 attached to diketone core, or by

varying the polymer molecular weight (for polymer-dye conjugates) and concentration or loading of the dye in the polymer (for blends).

[0009] In another aspect, the luminescent dye polymers and compositions can be readily processed into powders, films, particles (including *e.g.*, nanoparticles), fibers (including *e.g.*, nanofibers), coatings, bulk materials, gels, networks, assemblies, suspensions, composites, and the like.

[0010] The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. The description that follows more particularly exemplifies illustrative embodiments. In several places throughout the application, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.

[0011] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

Brief Description of the Figures

[0012] For the purpose of illustrating the invention, there are depicted in the drawings certain embodiments of the invention. However, the invention is not limited to the precise arrangements and instrumentalities of the embodiments depicted in the drawings.

[0013] **Fig. 1** is an illustration of the synthesis of the boron polylactide polymer, BF₂dbmPLA, from a primary alcohol functionalized difluoroboron dibenzoylmethane initiator, BF₂dbmOH.

[0014] **Fig. 2** shows normalized emission spectra for a BF₂dbmPLA thin film including total emission, fluorescence, phosphorescence with delayed fluorescence, and phosphorescence at low temperature.

[0015] Fig. 3 is a ^1NMR spectrum of nmbOH .

[0016] Fig. 4 illustrates the excitation and emission spectra of BF_2nmbOH .

[0017] Fig. 5 illustrates changes in the total emission spectrum of $\text{B}(\text{dbmOH})_2\text{Br}$ in 4:1 MeOH/EtOH and blue shift in phosphorescence as the temperature is lowered.

5

Detailed Description

[0018] Boron or aluminium substituted compounds (e.g., boron difluoride) can be bound to functionalized diketones (e.g., dibenzoylmethane) and used as initiators for polymerization of lactide and other monomers. Luminescent dye groups are introduced in the polymeric material (e.g., biodegradable and biocompatible polylactide) on specific sites in the polymer architecture with control. Block copolymers capable of nanoscale self assembly are possible. The compounds and compositions of the invention are useful as imaging agents, probes, readily processable photosensitizers, sensors (e.g., oxygen, ratiometric, both intensity and lifetime based; temperature; moisture; pH), laser dyes, optical fibers, waveguides, light emitting materials for displays, biocompatible polymers, solvatochromic materials, lithographic materials, photodegradable materials, photoactivated oxidizing agents, colorants, inks, reactive dyes, and the like. The photosensitizers can be used to produce a beneficial effect in photodynamic therapy for treatment of tumors.

[0019] Nanoparticles prepared from the disclosed luminescent dye polymers and compositions can be taken up and internalized by cells, which is useful for imaging. Also, the leaky vasculature of tumors allows for passive targeting via the enhanced permeation and retention (EPR) effect, with the possibility for imaging. The oxygen sensing ability of the luminescent dye polymers and compositions will allow analysis of the tumor. Generation of singlet oxygen (e.g. via phosphorescence quenching) can serve as a photodynamic therapy.

[0020] The disclosed luminescent dye polymers and compositions can be used to prepare oxygen sensors that can be placed in food or drug packages and allow measurement of oxygen within the package. The luminescent dye polymers and compositions can be used as a film, on fibers within the packaging, etc.

[0021] The following definitions are used, unless otherwise described: halo includes fluoro, chloro, bromo, or iodo. Alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to. Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic. Heteroaryl encompasses a radical attached via a ring carbon of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and one to four heteroatoms. The heteroatoms include non-peroxide oxygen, sulfur, silane, nitrogen and phosphorous wherein suitable substituents as known in the art can be attached to the hetero atoms, e.g., hydrogen, O, (C₁-C₁₂)alkyl, phenyl or benzyl, as well as a radical of an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a benz-derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto.

[0022] It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase).

[0023] Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only. They do not exclude other defined values or other values within defined ranges for the radicals and substituents. Specifically, (C₁-C₁₂)alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, hexyl and the like; (C₃-C₁₂)cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl and the like; (C₃-C₁₂)cycloalkyl(C₁-C₈)alkyl can be cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl,

cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, or 2-cyclohexylethyl and the like; (C₁-C₁₀)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy and the like; (C₂-C₁₂)alkenyl can be vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl and the like; (C₂-C₁₂)alkynyl can be ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 3-butylnyl, 1-pentylnyl, 2-pentylnyl, 3-pentylnyl, 4-pentylnyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-hexynyl and the like; (C₁-C₁₂)alkanoyl can be acetyl, propanoyl or butanoyl and the like; halo(C₁-C₆)alkyl can be iodomethyl, bromomethyl, chloromethyl, fluoromethyl, trifluoromethyl, 2-chloroethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, or pentafluoroethyl and the like; hydroxy(C₁-C₁₂)alkyl can be hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-hydroxybutyl, 4-hydroxybutyl, 1-hydroxypentyl, 5-hydroxypentyl, 1-hydroxyhexyl, or 6-hydroxyhexyl and the like; (C₁-C₁₂)alkoxycarbonyl can be methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, or hexyloxycarbonyl and the like; (C₁-C₁₂)alkylthio can be methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, pentylthio, or hexylthio and the like; (C₂-C₁₂)alkanoyloxy can be acetoxyl, propanoyloxy, butanoyloxy, isobutanoyloxy, pentanoyloxy, or hexanoyloxy and the like; (C₆-C₂₂)aryl can be phenyl, naphthyl, anthracyl, phenanthryl, pyryl, naphthacyl, pentacyl, or indenyl and the like; and (C₅-C₁₃)heteroaryl can be furyl, imidazolyl, triazolyl, triazinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, pyridyl, (or its N-oxide), thienyl, pyrimidinyl (or its N-oxide), indolyl, isoquinolyl (or its N-oxide) or quinolyl (or its N-oxide) and the like.

[0024] The polymers, Q, that are conjugated to the formula I compounds or blended with the formula II compounds include any polymeric material that can be conjugated or blended with a formula II compound. In one embodiment, non-toxic pharmaceutically acceptable, biologically stable (or biodegradable) polymers are preferred. Non-limiting examples of pharmaceutically acceptable polymers include polylactide (PLA), polyglycolide, lactide-glycolide copolymer, polycaprolactone, or polyethylene glycol polylactide polymers,

polyhydroxybutyrate (PHB), polyhydroxybutyrate-valerate copolymer (PHBV), polybutylene succinate (PBS), polybutylene adipate-co-terephthalate (PBAT), sugar based polymers (*e.g.*, cellulose or starch and the like), peptides, or mixtures thereof. Other exemplary polymers include polyurethanes, polyamides, polyesters, and vinylic polymers. Non-limiting examples of vinylic polymers include acrylates such as polymethyl methacrylate (PMMA), acrylonitrile butadiene styrene (ABS), styrene acrylonitrile (SAN), polystyrenes (PS), polyethylene (PE), polyethylenechlorinates (PEC), polybutadiene (PBD), polydicyclopentadiene (PDCP), polypropylene (PP) Polymethylpentene (PMP), and the like. Other exemplary polymers include silicon-based organic polymers such as polydimethylsiloxane (PDMS), polyesters such as polyethylene terephthalate (PET), glycolized polyester (PETG), polycarbonate (PC) and the like.

[0025] Additional exemplary polymers that can be prepared as Q groups or blended with the light emitting compounds include sol gels, aerogels, xerogels Cellulosic polymers, *e.g.*, hydroxypropylmethylcellulose, hydroxyl propyl cellulose, ethyl cellulose and the like; epoxy containing polymers, Ethylene vinyl alcohol, (E/VAL), fluoroplastics, *e.g.*, polytetrafluoroethylene (PTFE), , liquid crystal polymers, (LCP), melamine formaldehyde, (MF), phenol-formaldehyde plastic (PF), polyacetal, polyacrylates, polymethacrylates, polyacrylonitrile, (PAN), polyamide, (PA), *e.g.*, nylon, polyamide-imide (PAI), polyaryletherketone (PAEK), polyetheretherketone (PEEK), polyphenylene oxide (PPO), polyphenylene sulfide (PPS), polyphthalamide (PTA), Polysulfone (PSU), polyurethane (PU), polyurea, polyvinylchloride (PVC), polyvinylidene Chloride (PVDC), polyvinylidenedifluoride (PVDF) silicone polymers, poly(ethylene glycol) (PEG), poly(ethylene terephthalate) (PET), Polysiloxanes, silicones,

[0026] In one embodiment, the composition includes pharmaceutically acceptable polymers, FDA approved polymers or a mixture thereof. In another embodiment, the compositions include polymers prepared from vinyl monomers known in the art. In another embodiment, the invention also provides pharmaceutical compositions comprising a

compound of luminescent dye having formula II, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.

[0027] The term "amino acid" includes the residues of the natural amino acids (e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D or L form, as well as unnatural amino acids (e.g. phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, γ -carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citruline, α -methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine). The term also comprises natural and unnatural amino acids bearing a conventional amino protecting group (e.g. acetyl or benzyloxycarbonyl), as well as natural and unnatural amino acids protected at the carboxy terminus (e.g., as a (C₁-C₆)alkyl, phenyl or benzyl ester or amide; or as an α -methylbenzyl amide). Other suitable amino and carboxy protecting groups are known to those skilled in the art (See for example, T.W. Greene, *Protecting Groups In Organic Synthesis*; Wiley: New York, 1981, and references cited therein). An amino acid can be linked to the remainder of a compound of formula I through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of cysteine.


[0028] The term "peptide" describes a sequence of 2 to about 25 amino acids (e.g. as defined above) or peptidyl residues. The sequence may be linear or cyclic. For example, a cyclic peptide can be prepared or may result from the formation of disulfide bridges between two cysteine residues in a sequence. A peptide can be linked to the remainder of a compound of formula I through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of a cysteine. Preferably a peptide comprises 3 to about 25, or about 5 to about 21 amino acids. Peptide derivatives can be prepared as disclosed in U.S. Patent Nos. 4,612,302; 4,853,371; and 4,684,620. Peptide sequences specifically recited herein are written with the amino terminus on the left and the carboxy terminus on the right.

[0029] The compounds having formula I can be conjugated to a polymer through any suitable functional linking group. For example the conjugate can include dye-X, dye-X-Y, dye-X-R-Y, where X and Y can be initiators, terminators or coupling partner with a complimentary reactive group on a polymer (*e.g.*, at the chain end, main chain, side group, etc.). Alternatively, the diketone and the polymer may be linked to generate a “macroligand” (*e.g.*, dbmPLA or dbmPMMA) which is subsequently reacted with a B or Al (*e.g.* Y¹) precursor such as BF₃ to generate the luminescent material (*e.g.*, BF₂dbmPLA or BF₂dbmPMMA). A reactive group (initiator group) can be placed in a formula II compound using any means known in the art. The initiator groups can react with monomers, polymers or oligomers to form at least one polymer chain. In some cases the initiator can be part of the R¹, R², R⁵, X¹ or X² and used for direct coupling, (*e.g.*, initiation). Examples of initiator groups include primary alcohol linking group (*e.g.*, a group having the formula -(CH₂)_z-OH, where z is an integer from 1 to about 25; or -O-R⁶-O-H where R⁶ is alkylene, or alkenylene having at least two carbon atoms). Exemplary alcohol containing groups include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, -O-CH₂CH₂-OH or ArOH, and the like. Polymer groups prepared from vinyl groups can use a radical forming linking group (*e.g.*, a diazo or peroxy group). Other exemplary initiator groups include thiocarbonylthio compounds, such as dithioesters, dithiocarbamates, trithiocarbonates, xanthates, and the like.


[0030] The polymer chains can be formed using any compatible polymer synthesis method known in the art such as; 1) Nitroxide-mediated polymerization (NMP); 2) Reversible addition-fragmentation chain transfer (RAFT) polymerization using compounds having thiocarbonylthio initiator groups, such as dithioesters, dithiocarbamates, trithiocarbonates, and xanthates; 3) ATRP: using compounds having activated RCH₂X initiator groups where X is a halogen (*e.g.*, chlorine or bromine), α -haloesters such as α -bromobutyrolactone, allyl chloroacetate, vinyl chloroacetate, hydroxyethyl 2-bromobutyrate, t-butyl 2-bromobutyrate, glycidol 2-bromopropionate, and the like or α -haloamides such as 2-chloroacetamide and the like. Ring opening polymerization methods can use also compounds having alcohols or metal alkoxide, and carboxylic acid or metal carboxylate as initiator groups. Cationic polymerization methods can use compounds having alkyl halide, tosylate, Lewis acid or

alcohol initiator groups. Anionic polymerization reactions can use compounds having alcoholic or nucleophilic base initiator groups, such initiators for anionic polymerization are known in the art.

[0031] The invention includes dimers, *e.g.*, compounds where R^3 and R^4 taken together with the Y^1 atom form a chelate ring having the formula:




e.g., R^3 and R^4 form a ring together with the atom to which they are attached to provide a compound having formula III



III

where each R^1 , R^2 , X^1 , X^2 and R^5 are independently selected from the definitions above. Additionally, R^3 and R^4 taken together form a bidentate chelate, such as deprotonated acid or diacid group, $HOC(=O)CH_2C(=O)OH$ (malonic acid) or $HOC(=O)CH_2C(=O)OH$ (oxalic acid), or chelating group such as acid-alcohol, acid-ether, with two donor groups, or R^3 and R^4 taken together with the boron atom form a ring having the formula:

[0032] Preferred R^1 and R^2 groups include phenyl, naphthyl, anthracyl or have the formula



where each X^4 is independently O, S, NR^a , or PR^a , where R^a is hydrogen, alkyl or aryl.

[0033] More preferred R^1 and R^2 groups include phenyl, naphthyl, anthracyl or have the formula:



[0034] Even more preferred R^1 and R^2 groups include phenyl, or naphthyl.

- 5 [0035] Specific substituents include halo, hydroxy(C_1 - C_{12})alkyl, halo(C_1 - C_{12})alkyl, $R^{15}O(C_1$ - $C_{12})$ alkyl, $R^{15}O(C_1$ - $C_{12})$ alkyl-O-, -OR¹⁵, -CO₂R¹⁵, -OC(O)R¹⁶, -C(O)R¹⁶, -NR¹³R¹⁴, -N(R²³)C(O)R²⁴, -C(O)NR¹⁷R¹⁸, -SR¹⁹, or -SO₂R²⁰.















[0036] Preferred R^3 and R^4 substituents include electron withdrawing groups such as halo, e.g., fluorine.

















- 10 [0037] Preferred R^3 and R^4 substituents include electron donating group such as OR¹⁵.


[0038] The polymeric luminescent dye compounds and compositions can be processed into materials that can be combined in medical devices such as oxygen sensors. The sensors can be used to detect low levels of oxygen in, e.g., blocked vasculature, hypoxic tumors.

- [0039] Diketone synthesis is modular. Different R^1 and R^2 groups may be added to either
 15 side of the diketone to modulate optical properties (e.g., luminophores). Additionally, the R^1 and R^2 can contain a linker group (e.g. initiator, terminating agent, coupling partner) or a group that can be readily converted using standard chemical techniques to an initiator site. Various commercially available starting compounds that have initiator sites may be readily used or modified to form compounds having formula I. The compounds having formula II
 20 can be modified to tune polymer architecture, materials and optical properties. Block copolymers can be also prepared, by sequential monomer addition or by modifying dibenzoylmethane and related diketones with two different kinds of initiator sites. These can self assemble to generate nanostructured films, bulk materials, solution assemblies, particles, etc. Other polymer compositions can be also prepared, e.g., by varying the initiator group. A
 25 preferred initiator group for lactide or caprolactone ring opening polymerizations is a primary alcohol. Alpha bromoesters are good initiator groups for ATRP, affording PMMA and other

polymers. The diketone ligand molecules can be readily prepared using standard methods known to a person skilled in organic synthesis. In addition many ligands are commercially available and have groups that can be used or transformed into initiator groups. Exemplary ligand molecules include molecules having the formulas below:







[0040] Synthesis of the boron polymer, BF₂dbmPLA, begins with hydroxylfunctionalized difluoroboron dibenzoylmethane. BF₂dbmOH (**1**), is prepared for use as an initiator in the ring opening polymerization of lactide to produce BF₂dbm end-functionalized polylactide, BF₂dbmPLA (**2**) (**Fig. 1**). The boron complex, BF₂dbmOH, **1**, is synthesized from dbmOH (**21**) and BF₃•Et₂O in CH₂Cl₂ (60 °C, 1 hour). After purification by recrystallization from acetone/hexanes, air stable, bright yellow needles are obtained in good yield (75%). The boron polymer, BF₂dbmPLA, **2**, is generated from BF₂dbmOH and DL-lactide using tin octoate, Sn(oct)₂, as the ROP catalyst under solvent-free conditions (1:lactide:Sn(oct)₂ = 1:200:1/50) with heating at 130 °C under nitrogen. The reaction is stopped after 1.5 hours (~50% monomer conversion) to avoid broader molecular weight distributions (i.e. higher PDIs) noted for longer reaction times, suggestive of transesterification and thermal depolymerization.

After purification by precipitation from CH₂Cl₂/cold MeOH and CH₂Cl₂/hexanes, a pale greenish yellow polymer is obtained (75% yield, corrected for monomer consumption).


Molecular weight data determined by gel permeation chromatography (GPC) and ¹H NMR spectroscopy are in good agreement: Mn(GPC/RI) = 8,800, PDI = 1.09; Mn (NMR) = 8,600.

- 5 Furthermore, key proton resonances associated with the boron dbm end group are evident and shifted as compared to the initiator **1** (e.g. BF₂dbmOCH₂CH₂OR: R = H, 4.04 ppm; R = PLA, 4.32 ppm). The synthesis is illustrated in **Fig. 1**.

Examples

- [0041] **Materials.** 3,6-Dimethyl-1,4-dioxane-2,5-dione (D,L-lactide, Aldrich) was
10 recrystallized twice from ethyl acetate and stored under nitrogen. Solvents, CH₂Cl₂ and THF, were dried and purified by passage through alumina columns. Tin(II) 2-ethylhexanoate (Sn(oct)₂, Spectrum), boron trifluoride diethyl etherate (Aldrich, purified, redistilled) and all other reagents and solvents were used as received without further purification.


- [0042] **Methods.** ¹H NMR (300 MHz) spectra were recorded on a UnityInova 300/51
15 instrument in CDCl₃ unless indicated otherwise. ¹H NMR spectra were referenced to the signal for residual protio chloroform at 7.26 ppm and coupling constants are given in hertz. UV/vis spectra were recorded on a Hewlett-Packard 8452A diode-array spectrophotometer. Fluorescence spectra were measured on a Spex Fluorolog 2+2 spectrofluorometer. Molecular weights were determined by GPC (THF, 20 °C, 1.0 mL/min) vs polystyrene standards with RI
20 and UV/vis detection (λ = 396 nm), and a correction factor of 0.58 was applied to all data. Reported yields are corrected for monomer consumption. Polymer Labs 5μm mixed-C columns along with Hewlett-Packard instrumentation (Series 1100 HPLC) and Viscotek software (TriSEC GPC Version 3.0, Viscotek Corp) were used in the GPC/RI or GPC/UV analysis. Elemental analysis was performed by Atlantic Microlab, Inc., Norcross, GA.

Preparation 1: DbmOH (1-(4-(2-hydroxyethoxy)phenyl)-3-phenylpropane-1,3-dione).

[0043] DbmOH was prepared as previously reported by Bender *et al. J. Am. Chem. Soc.* **2002**, *124*, 8526-8527. with the following modifications. After purification of the crude

5 product (3 g) by column chromatography, the solid was dissolved in hot 60:40 hexanes/EtOAc, sonicated briefly (~3-5 sec) until crystallization commenced, then the flask was allowed to cool to room temperature (~2 h), then further cooled in the freezer (-15 °C; ~12 h). The solid was collected by filtration, washed with cold 60:40 hexanes/EtOAc (~5 mL) and dried *in vacuo* to give bright yellow needles with a greenish hue 1.8 g (first crop). The

10 mother liquor was concentrated to give pale yellow solid, which was re-subjected to the aforementioned crystallization procedure: 0.63 g (second crop; larger needles). Yield: 2.4 g (80%).

Preparation 2: BF₂dbmOH (1).**1**

[0044] DbmOH (100.0 mg, 0.352 mmol) was added to a flame-dried 2-neck round bottom flask under nitrogen, and dissolved in CH₂Cl₂ (15 mL) to give a pale yellow solution. Boron trifluoride diethyl etherate (44 µL, 0.352 mmol) was added via syringe and the solution turned bright yellow. The flask was equipped with a reflux condenser and heated in an oil bath at 60

20 °C (1 h). The solution was cooled to room temperature and the solvent was removed *on vacuo*, giving a yellow foam. The crude product was recrystallized in 10:90 acetone:hexanes to give BF₂dbmOH as bright yellow needles: 87 mg (75%). ¹H NMR (CDCl₃) δ 8.15 (m, 4H, 2',6'-ArH, 2'',6''-ArH), 7.68 (t, *J* = 7.3, 1H, 4'-ArH), 7.55 (t, 2H, *J* = 7.6, 3'',5''-ArH), 7.07 (d, *J*

= 9.1, 2H, 3',5'-ArH), 7.12 (s, 1H, COCHCO), 4.23 (t, $J = 4.5$, 2H, HOCH₂CH₂OAr), 4.04 (t, $J = 4.4$, 2H, HOCH₂CH₂OAr), 1.96 (t, $J = 6.2$, 1H, HOCH₂CH₂OAr). M.p. 170-172 °C. Anal. calcd for C₁₇H₁₅BF₂O₄: C, 61.48; H, 4.55. Found: C, 61.72; H, 4.63. UV/vis (CH₂Cl₂): $\lambda_{\max}(\text{sh}) = 397 \text{ nm}$, $\epsilon = 53,000 \text{ M}^{-1}\text{cm}^{-1}$.

5 Example 1: Preparation of BF₂dbmPLA Polymer.

[0045] BF₂dbmOH (10 mg, 0.030 mmol), lactide (0.865 g, 6.00 mmol) and Sn(oct)₂ (0.24 mg, 0.60 μmol) (loading: 1:200:1/50) in hexanes were combined in a sealed Kontes flask under N₂. The entire bulb of the flask was submerged in a 130 °C oil bath for 1.5 h. Crude polymer was purified by precipitation from CH₂Cl₂/cold MeOH. The polymer was collected
10 by centrifugation, the filtrate was decanted, and the gummy solid was washed with additional cold MeOH (2 $\times$). The resulting solid was reprecipitated from CH₂Cl₂/hexanes, collected by centrifugation, washed with hexanes (2 $\times$), and dried *in vacuo* to give a very pale greenish yellow foam: 320 mg (75%, corrected for 49.5% monomer conversion). M_n (GPC/RI) = 8,800, PDI = 1.09; M_n (NMR) = 8,600. ¹H NMR (CDCl₃) δ 8.16 (t, $J = 8.2$, 4H, 2',6'-ArH,
15 2'',6''-ArH), 7.69 (t, $J = 7.6$, 1H, 4'-ArH), 7.57 (m, 2H, 3'',5''-ArH), 7.12 (s, 1H, COCHCO), 7.04 (d, $J = 8.5$, 2H, 3',5'-ArH), 5.12-5.30 (m, broad, 119H, PLA CH), 4.54 (d, $J = 4.9$, 2H, CH₂CH₂OAr), 4.32 (m, 2H, CH₂CH₂OAr), 2.70 (s, broad, 1H, PLA OH), 1.54-1.60 (m, broad, 361H, PLA CH₃). UV/vis (CH₂Cl₂): $\lambda_{\max}(\text{sh}) = 396 \text{ nm}$, $\epsilon = 50,100 \text{ M}^{-1}\text{cm}^{-1}$. $T_g = 52 \text{ }^\circ\text{C}$. $T_d = 298 \text{ }^\circ\text{C}$.

20 Examples 2-8: Preparation of BF₂dbmPLA Polymers.

[0046] BF₂dbmPLA (2-7). BF₂dbmOH (10.0 mg, 0.0300 mmol), lactide (0.865 g, 6.00 mmol) and Sn(oct)₂ (0.24 mg, 0.6 μmol) (loading: 1:200:1/50) in hexanes were combined in a sealed Kontes flask under N₂. The entire bulb of the flask was submerged in a 130 °C oil bath. The reaction was stopped at 15 min, 20 min, 50 min, 1.5 hours, 2.5 hours, and 16 hours.
25 Crude polymer was purified by precipitation from CH₂Cl₂/cold MeOH. The polymer was collected by centrifugation, the filtrate was decanted, and the gummy solid was washed with additional cold MeOH (2 $\times$). The resulting solid was reprecipitated from CH₂Cl₂/hexanes,

collected by centrifugation, washed with hexanes (2×), and dried in vacuo to give a greenish yellow foam (the color of the foam tends to be paler when MW increases).

Physical Characterization of Polymers 2-8:

- [0047] (2) M_n (GPC/RI) = 8,800, PDI = 1.09; M_n (NMR) = 8,600. ^1H NMR (CDCl_3) δ 8.16 (t, J = 8.2, 4H, 2',6'-ArH, 2'',6''-ArH), 7.69 (t, J = 7.6, 1H, 4'-ArH), 7.57 (m, 2H, 3'',5''-ArH), 7.12 (s, 1H, COCHCO), 7.04 (d, J = 8.5, 2H, 3',5'-ArH), 5.12-5.30 (m, broad, 119H, PLA CH), 4.54 (d, J = 4.9, 2H, $\text{CH}_2\text{CH}_2\text{OAr}$), 4.32 (m, 2H, $\text{CH}_2\text{CH}_2\text{OAr}$), 2.70 (s, broad, 1H, PLA OH), 1.54-1.60 (m, broad, 361H, PLA CH_3). UV/vis (CH_2Cl_2): $\lambda_{\text{max}}(\text{sh})$ = 396 nm, ϵ = 50,100 $\text{M}^{-1}\text{cm}^{-1}$. T_g = 52 °C. T_d = 298 °C.
- 10 [0048] (3) 36.0 mg (32%, corrected for 13% monomer conversion). M_n (GPC/RI) = 3,000, PDI = 1.10; M_n (NMR) = 3,000. NMR data similar to above. UV/vis (CH_2Cl_2): $\lambda_{\text{max}}(\text{sh})$ = 396 nm, ϵ = 52,700 $\text{M}^{-1}\text{cm}^{-1}$.
- [0049] (4) 58.7 mg (40%, corrected for 17% monomer conversion). M_n (GPC/RI) = 4,500, PDI = 1.06; M_n (NMR) = 5,000. NMR data similar to above. UV/vis (CH_2Cl_2):
- 15 $\lambda_{\text{max}}(\text{sh})$ = 396 nm, ϵ = 51,800 $\text{M}^{-1}\text{cm}^{-1}$.
- [0050] (5) 200.1 mg (68%, corrected for 34% monomer conversion). M_n (GPC/RI) = 7,000, PDI = 1.11; M_n (NMR) = 6,800. NMR data similar to above. UV/vis (CH_2Cl_2): $\lambda_{\text{max}}(\text{sh})$ = 396 nm, ϵ = 50,300 $\text{M}^{-1}\text{cm}^{-1}$.
- [0051] (6) 359.0 mg (83%, corrected for 50% monomer conversion). M_n (GPC/RI) =
- 20 10,600, PDI = 1.09; M_n (NMR) = 8,600. NMR data similar to above. UV/vis (CH_2Cl_2): $\lambda_{\text{max}}(\text{sh})$ = 396 nm, ϵ = 51,000 $\text{M}^{-1}\text{cm}^{-1}$.
- [0052] (7) 492.7 mg (89%, corrected for 64% monomer conversion). M_n (GPC/RI) = 14,900, PDI = 1.10; M_n (NMR) Not available due to weak initiator signal. UV/vis (CH_2Cl_2): $\lambda_{\text{max}}(\text{sh})$ = 396 nm, ϵ = 49,100 $\text{M}^{-1}\text{cm}^{-1}$.

[0053] (8) 737.5 mg (87%, corrected for 98% monomer conversion). M_n (GPC/RI) = 22,600, PDI = 1.66; M_n (NMR) Not available due to weak initiator signal. UV/vis (CH_2Cl_2): $\lambda_{\text{max}}(\text{sh}) = 396 \text{ nm}$, $\epsilon = 46,300 \text{ M}^{-1}\text{cm}^{-1}$. [where did this example come from?]

Example 9: Film Preparation.

5 [0054] BF_2dbmPLA (2-3 mg) of sample 2 was dissolved in CH_2Cl_2 (2 mL) to give a homogenous solution. One drop of the solution was withdrawn via a pipet and was cast on the surface of a quartz luminescent cuvet to form a very thin film. The film was allowed to dry for ~10 min in air (RT) before taken to measurement of molecular weight effects on emission properties. (The Same procedure was followed for samples 3-8.)

10 Summary of BF_2dbmOH initiator and BF_2dbmPLA polymer properties.

[0055] The optical properties of the boron initiator BF_2dbmOH and polymer 2 prepared in Example 1, were investigated in solution and in the solid state. UV/vis spectroscopic data for BF_2dbmPLA in CH_2Cl_2 solution ($\lambda_{\text{max}} = 396 \text{ nm}$, $\epsilon = 50,100 \text{ M}^{-1}\text{cm}^{-1}$) are similar to the boron initiator 1 ($\lambda_{\text{max}} = 397 \text{ nm}$, $\epsilon = 53,000 \text{ M}^{-1}\text{cm}^{-1}$) and show high molar absorptivities
 15 characteristic of this family of compounds. Upon excitation with a UV lamp (long wavelength setting; excitation wavelength ~365 nm) intense blue fluorescence is observed for CH_2Cl_2 solutions of BF_2dbmOH and BF_2dbmPLA ($\lambda_{\text{em}} \sim 440 \text{ nm}$), and in both cases fluorescence quantum yields, ϕ_F , are very high (~90-95%). (Compare to BF_2 compounds of dbm, 20%, and 1,3-di(4-methoxyphenyl)propane-1,3-dione, 85%). Solutions appear blue
 20 even in ambient light or upon when illuminated with a flashlight, due to near UV excited fluorescence. In the solid state, in contrast, BF_2dbmOH crystals display greenish yellow emission ($\lambda_{\text{em}} = 540 \text{ nm}$) that is sensitive to the solid form. (Powders emit at ~512 nm). Fluorescence lifetimes for the initiator and polymer (solution, solid state) are all in the nanosecond range and fit to single-exponential decay, further verifying sample homogeneity.
 25 Boron polymer foams (i.e. obtained after precipitation and drying) and thin films cast from dilute CH_2Cl_2 solution also show blue fluorescence (~440 nm, Fig. 2), but lifetimes fit to double exponential decay. Two photon absorption was also confirmed for the BF_2dbmPLA

foam via laser scanning confocal microscopy with femtosecond Ti:sapphire laser excitation ($\lambda_{\text{ex}} = 790 \text{ nm}$). Samples (e.g. powders, nanoparticles) continue to emit strongly even after months in aqueous suspension.

[0056] The BF_2dbmPLA polymer also exhibits long lived, green room temperature phosphorescence (RTP). The phosphorescence is sensitive to oxygen quenching, serving as a highly sensitive optical oxygen sensor. Films also exhibit delayed fluorescence, a small shoulder on the high energy side of the phosphorescence emission band, which is temperature sensitive and disappears at 77 K (Fig. 2).

[0057] Properties of BF_2dbmPLA materials vary with polymer molecular weight. BF_2dbmPLA polymers of molecular weights ranging from ~2-20 kDa all exhibit high quantum yields ranging from ~75-90%. All methylene chloride solutions display intense blue fluorescence (~440 nm), however in the solid state (films, powders, etc.) BF_2dbmPLA emission varies from green to blue, depending on the polymer molecular weight. This provides a very simple method of tuning emission color in dye-polymer conjugates.

15 Example 10: $\text{BF}_2\text{dbmOH/PLA}$ Blends.

[0058] **PLA (Control).** Ethylene glycol (5.74 mg, 92.4 μmol), lactide (0.866 g, 6.00 mmol) and $\text{Sn}(\text{Oct})_2$ (1.50 mg, 3.70 μmol) (Loading 1:65:1/25) in hexanes were combined in a sealed Kontes flask under N_2 . The entire bulb of the flask was submerged in a 130 °C oil bath for 20 min. Crude polymer was purified by precipitation from CH_2Cl_2 /cold MeOH (to remove unreacted monomer). The polymer was collected by centrifugation, the filtrate was decanted, and the gummy solid was washed with additional cold MeOH (2 $\times$). The resulting solid was reprecipitated from CH_2Cl_2 /hexanes (to remove the Sn catalyst), collected by centrifugation, washed with hexanes (2 $\times$), and dried *in vacuo* to give a white foam: 0.66 g (84%, corrected for 92% monomer conversion). $M_n(\text{GPC/RI}) = 8,800$, PDI: 1.09; $M_w(\text{GPC/MALLS}) = 9,400$, PDI = 1.03. $M_n(\text{NMR}) = 8,900$. $^1\text{H NMR}$ (CDCl_3) δ $^1\text{H NMR}$ (CDCl_3) 5.11-5.30 (125H, m, broad, CH), 4.33 (4H, m, CH_2CH_2), 2.69 (m, 2H, OH), 1.54-1.60 (373H, m, broad, CH_3).

BF₂dbmOH/PLA Blend - Film Preparation.

[0059] PLA was dissolved in 10 mL CH₂Cl₂ and different amount of BF₂dbmOH was added to the solution to form different fluorophore percentages (F%) in the blend. The solution then was slowly swirled to dry under N₂ to provide films on the wall of the vial.

5

Table 1

Sample No.	BF ₂ dbmOH	PLA	F%
9	2.1 mg	25 mg	8.3
10	3.2 mg	50 mg	6.4
11	2.1 mg	50 mg	4.3
12	1.3 mg	50 mg	2.7
13	1.0 mg	50 mg	2.0
14	0.6 mg	100 mg	0.6

BF₂dbmOH/PLA Blend - Film properties.

[0060] Intense blue fluorescence is observed for BF₂dbmOH/PLA blends cast as films. Under oxygen free conditions, green phosphorescence is also observed. Fluorescence emission color can be tuned (*e.g.* from blue to green), by varying the dye loading in the film.

10

Example 11: Preparation of BF₂dbmPLA Polymer Fiber.

[0061] A polymer fiber (~10 inches) was drawn from the crude reaction mixture prepared in example 1 using a glass pipet. When one end of the fiber is excited using UV lamp (λ_{ex} = 365 nm, RT, air), the excited end of the fiber emits blue light, which passes through and along part of the fiber. The far end of the fiber that is outside the range of the UV light source emits light that is red shifted and green color. This is also noted when excitation is performed with a pulsed nitrogen laser (λ_{ex} = 337 nm).

15

Example 12: Preparation of BF₂dbmPLLA.

[0062] BF₂dbmOH (10.0 mg, 0.034 mmol, 1 eq), L-lactide (0.49 g, 3.40 mmol 100 eq.) and Sn(Oct)₂ (0.55 mg, 0.0014 mmol, 1/50 eq.) in hexanes were combined in a sealed Kontes

20

flask under N₂. The entire bulb of the flask was submerged in a 130 °C oil bath (to prevent the monomer from solidifying on the upper walls of the flask) for 2.5 hours. Crude polymer was purified by precipitation from CH₂Cl₂/cold MeOH (to remove unreacted monomer). The polymer was collected by centrifugation, the filtrate was decanted, and the powdery solid was washed with additional cold MeOH (2×). The resulting solid was reprecipitated from CH₂Cl₂/hexanes (to remove the Sn catalyst), collected by centrifugation, washed with hexanes (2×), and dried in vacuo to give a pale green powder (0.37 g, 75%). GPC data: M_n 11,000; PDI: 1.09.

Example 13: Preparation of BF₂dbmPCL.

10 [0063] BF₂dbmOH (20.0 mg, 0.068 mmol), ε-caprolactone (1.55 g, 13.6 mmol) and Sn(Oct)₂ (0.55 mg, 0.0014 mmol) in hexanes were combined in a sealed Kontes flask under N₂. The entire bulb of the flask was submerged in a 110 °C oil bath for 36 h. Crude polymer was purified by precipitation from CH₂Cl₂/cold MeOH (to remove unreacted monomer). The polymer was collected by centrifugation, the filtrate was decanted, and the gummy solid was washed with additional cold MeOH (2×). The resulting solid was reprecipitated from CH₂Cl₂/hexanes (to remove the Sn catalyst), collected by centrifugation, washed with hexanes (2×), and dried *in vacuo* to give a white powder (1.25g, 86%). GPC (THF): M_n: 18,400; PDI: 1.08

Example 14: Preparation of BF₂dbmPCL-*b*-PLA.


20 [0064] BF₂dbmPCL (1.0 g, 0.054 mmol), D,L-Lactide (2.161 g, 14.85 mmol) and Sn(Oct)₂ (0.49 mg, 0.0011 mmol) in hexanes were combined in a sealed Kontes flask under N₂. The entire bulb of the flask was submerged in a 130 °C oil bath for 5.5 hours. Crude polymer was purified by precipitation from CH₂Cl₂/cold MeOH (to remove unreacted monomer). The polymer was collected by centrifugation, the filtrate was decanted, and the powder like solid was washed with additional cold MeOH (2×). The resulting solid was reprecipitated from CH₂Cl₂/hexanes (to remove the Sn catalyst), collected by centrifugation,

washed with hexanes (2×), and dried *in vacuo* to give a pale green solid (1.25g, 86%). GPC Data: M_n : 41,600; PDI: 1.12

Example 15: Preparation of BF₂dbmPMMA.

- [0065] A preliminary experiment was performed with dbmPMMA and BF₃ in CH₂Cl₂ solution. The resulting white polymer exhibited intense blue light emitting property under UV light (λ_{ex} = 365nm). This suggests that B polymeric complexes may also be prepared by the chelation method, with preformed dbm ligand-containing polymer.

Example 16: Preparation of nmbOH.



- [0066] 1-(4-(2-(2-(2-methylnaphthoate)ethoxy)ethoxy)phenyl)ethanone (2.00g, 7.57mmol) and 2-methyl naphthoate (2.11g, 11.36mmol) were added to a 25 mL flame dried Schlenk flask under N₂. 10 mL THF was added to dissolve the mixture under Ar. NaH (0.272g, 11.36mmol) was added to a 100 mL 2-necked round-bottom flask under N₂, and 30 mL THF was added to the flask under Ar. The mixture from the Schlenk flask was transferred via cannula to the round-bottom flask containing a suspension of NaH/THF. The mixture in the flask was stirred at room temperature for 10 min before adding a condenser to the round-bottom flask under N₂. Then the bulb of the flask was submerged in an oil bath at 45 °C for 2.5 h. The maroon reaction mixture was cooled to room temperature and was neutralized with saturated NaHCO₃ aqueous solution. The mixture was extracted with EtOAC (50 mL × 2) and brine (100 mL) was added to the combined organic layers. The collected organic solution was dried over Na₂SO₄ and was filtered by a gravity funnel. The solution was dried *in vacuo* for 16 h to result in viscous dark maroon oil. Acetic acid (30 mL), THF (30 mL) and water (10 mL) were added to a 500 mL flask containing the oil. The flask was submerged in an oil bath at 45 °C for 36 h. Then the reaction mixture was dried *in vacuo* and HCl (250 mL 1M) was added

to the 500 mL flask. Orange precipitate was formed and was collected by gravity filtration. The precipitate was dried *in vacuo* for 15 h and the crude product was obtained by separating the precipitate from a silica gel column using 60:40 hexanes/acetone as the solvent. The collected desired component was dried *in vacuo* and was recrystallized from 60:40
 5 hexanes/EtOAc to give silver metallic looking snow-flake like crystals. (1.14g, 52%) Anal. calcd for $C_{21}H_{18}O_4$: C, 75.43; H, 5.43; O, 19.14. Found: C, 75.47; H, 5.41; O, 19.21. m.p.= 136-137 °C. UV/vis (CH_2Cl_2): $\lambda_{max}(sh) = 365\text{ nm}$, $\epsilon = 53,600\text{ M}^{-1}\text{cm}^{-1}$. The 1H NMR spectrum is illustrated in Fig. 4.

Example 17: Preparation of BF_2nbmOH .

10 [0067] NbmOH (500.0 mg) was added to a flame-dried 2-neck round bottom flask under nitrogen, and dissolved in CH_2Cl_2 (15 mL) to give a pale yellow solution. Boron trifluoride diethyl etherate (40 μ L) was added via syringe and the solution turned bright yellow. The flask was equipped with a reflux condenser and heated in an oil bath at 60 °C (1 h). The solution was cooled to room temperature and the solvent was removed *on vacuo*. The crude
 15 product was recrystallized in 10:90 acetone:hexane to give BF_2nbmOH as dark yellow needles: 401 mg (72%). Anal. calcd for $C_{21}H_{17}O_4BF_2$: C, 66.21; H, 4.48; Found: C, 66.40; H, 4.54. $\lambda_{max}(sh) = 415\text{ nm}$, $\epsilon = 52,100\text{ M}^{-1}\text{cm}^{-1}$. The excitation and emission spectra in CH_2Cl_2 ($\lambda_{ex}=415\text{ nm}$ and $\lambda_{em}=446\text{ nm}$) are illustrated in Fig. 4.

$BF_2nbmPLA$ (First batch GZ1-174 April 16th)


20 Examples 18: Preparation of $BF_2nbmPLA$ polymer.

[0068] BF_2nbmOH (10.0 mg, 0.262 mmol), lactide (0.5655 g, 3.92mmol) and $Sn(oct)_2$ (0.21 mg, 0.52 μ mol) (loading: 1:150:1/50) in hexanes were combined in a sealed Kontes flask under N_2 . The entire bulb of the flask was submerged in a 130 °C oil bath (to prevent the monomer from solidifying on the upper walls of the flask) for ~2 h. Crude polymer was
 25 purified by precipitation from CH_2Cl_2 /cold MeOH to remove unreacted monomer. The polymer was collected by centrifugation, the filtrate was decanted, and the gummy solid was

washed with additional cold MeOH (2×). The resulting solid was reprecipitated from CH₂Cl₂/hexanes to remove the Sn catalyst, collected by centrifugation, washed with hexanes (2×), and dried in vacuo to give a bright yellow foam: 168 mg (63%, corrected for 48 % monomer conversion.). M_n (GPC/RI) = 8,600, PDI = 1.11; M_n (NMR) = 8,730; $\lambda_{\text{max}}(\text{sh}) =$
5 414 nm, $\epsilon = 27,000 \text{ M}^{-1}\text{cm}^{-1}$.

Examples 19: BF₂nbmOH initiator and BF₂nbmPLA polymer properties.

[0069] BF₂nbmOH also exhibits a high UV/vis extinction coefficient ($\sim 52,100 \text{ M}^{-1}\text{cm}^{-1}$) at $\lambda_{\text{max}} = 415 \text{ nm}$, and a strong fluorescence emission at 446 nm. UV/vis absorption spectral data
10 for BF₂nbmPLA are as follows: $\lambda_{\text{max}}(\text{sh}) = 414 \text{ nm}$, $\epsilon = 27,000 \text{ M}^{-1}\text{cm}^{-1}$, and intense blue fluorescence at $\sim 450 \text{ nm}$ is observed. Under a nitrogen atmosphere, BF₂nbmPLA material also displays long-lived greenish-yellow phosphorescence ($\sim 540 \text{ nm}$) after excitation and short-lived fluorescence ceased. Surprisingly, this material also displays phosphorescence even for films under air. When a vial was coated with a thin film and sealed under air,
15 excitation revealed the expected fluorescence but after the lamp was turned off, phosphorescence gradually appeared too. Oxygen in the film may be depleted by phosphorescence quenching, generating a reactive singlet oxygen byproduct by photoactivation. Once depleted of quencher, films may phosphoresce until new oxygen quencher can diffuse into the film. In this way, these materials can serve as oxygen
20 scavengers and activators, and optical reporters of gas diffusion rates even under ambient conditions. It is possible to tune the color of the fluorescence and phosphorescence by varying the polymer molecular weight. Materials also display different emission colors at different temperatures, which are also polymer molecular weight dependent.

Example 20: Preparation of B(dbmOH)₂Br

[0070] DbmOH (200mg, 0.703 mmol) was dissolved in dry CH₃CN (5 mL) in a flame-dried 2-neck round bottom flask equipped with a condenser under N₂. The flask was submerged in an ice bath for 15 min, then BBr₃ (88.1 mg, 33 μ L /0.351 mmol) was injected via a Hamilton syringe and the mixture stirred in the ice bath for 5 min. The flask was then removed from the ice bath, warmed to RT, and acetone was added to form a yellow precipitate. The crude product was collected by gravity filtration, washed with acetone, and dried in vacuo, then recrystallized from CH₃CN/acetone to form a deep yellow powder: 151 mg, 74%. UV/vis (EtOH): λ_{max} = 426 nm; ϵ = 52,300 M⁻¹cm⁻².

Properties

[0071] The UV/vis spectrum for B(dbmOH)₂Br in EtOH shows λ_{max} = 426 nm. In 4:1 MeOH:EtOH, the emission exhibits dramatic color changes with temperature, ranging from blue at room temperature to green, orange, red, orange, greenish yellow as the sample is progressively cooled and forms a glass at 77 K.

[0072] The total emission spectrum of B(dbmOH)₂Br in 4:1 MeOH/EtOH upon cooling after excitation by a UV lamp (λ_{max} = 365 nm) is illustrated in Fig. 5. The higher energy peak at about 480 nm is the fluorescence peak, and the progressively blue-shifting lower energy peak at about 600 nm is the phosphorescence peak. Temperature: from bottom to top at about -80 °C (~193K) to about -196 °C (~77K) (middle temperature not measured).


[0073] All patents, patent applications and literature cited in the specification are hereby incorporated by reference in their entirety. In the case of any inconsistencies, the present

disclosure, including any definitions therein will prevail. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the invention.

- 5 **[0074]** Having thus described the preferred embodiments of the present invention, those of skill in the art will readily appreciate that the teachings found herein may be applied to yet other embodiments within the scope of the attached claims.

What is claimed is:

1. A luminescent dye compound having formula I:




I

wherein R^1 and R^2 are independently (C_6-C_{22}) aryl or (C_5-C_{21}) heteroaryl; R^1 and R^2 are optionally independently substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 substituent groups; where the substituent groups are halo, (C_1-C_{12}) alkyl, hydroxy (C_1-C_{12}) alkyl, halo (C_1-C_{12}) alkyl, $R^{15}O(C_1-C_{12})$ alkyl, $R^{15}O(C_1-C_{12})$ alkyl-O-, (C_2-C_{12}) alkenyl, (C_7-C_{26}) aralkyl, (C_5-C_{13}) heteroaryl, $-OR^{15}$, oxo ($>C=O$), $-CN$, $-NO_2$, $-CO_2R^{15}$, $-OC(O)R^{16}$, $-C(O)R^{16}$, $-NR^{13}R^{14}$, $-N(R^{23})C(O)R^{24}$, $-C(O)NR^{17}R^{18}$, $-SR^{19}$, $-SO_2R^{20}$, $-OSiR^{25}_3$, $-SiR^{25}_3-SiR^{25}_i(OR^{25})_j$, $-P(OR^{25})_3$, $-PR^{25}_3$, isocyanate, isothiocyanate, urea, or thiourea; or two substituent groups can form a ring together with the atom to which they are attached optionally having from 3 to 8 ring atoms and optionally having 1, 2, or 3 heteroatoms; each R^{25} is independently hydrogen, alkyl or aryl; and i and j are independently integers from 1-3 wherein the sum of i and j is 3;


Y^1 is Al or B; X^1 and X^2 are independently a bond, alkyl, alkenyl, alkynyl or aryl, optionally substituted with 1, 2, 3, 4, 5, or 6 substituent groups; where the substituent groups are halo, (C_1-C_{12}) alkyl, hydroxy (C_1-C_{12}) alkyl, halo (C_1-C_{12}) alkyl, $R^{15}O(C_1-C_{12})$ alkyl, $R^{15}O(C_1-C_{12})$ alkyl-O-, (C_2-C_{12}) alkenyl, (C_7-C_{26}) aralkyl, (C_5-C_{13}) heteroaryl, $-OR^{15}$, oxo ($>C=O$), $-CN$, $-NO_2$, $-CO_2R^{15}$, $-OC(O)R^{16}$, $-C(O)R^{16}$, $-NR^{13}R^{14}$, $-N(R^{23})C(O)R^{24}$, $-C(O)NR^{17}R^{18}$, $-SR^{19}$, $-SO_2R^{20}$, $-OSiR_3$, $-SiR_3$, $-SiR^{25}_i(OR^{25})_j$, $-PR_3$, $-P(OR)_3$, isocyanate, isothiocyanate, urea, thiourea or two substituent groups can form a ring together with the atom to which they are attached optionally having from 3 to 8 ring atoms and optionally having 1, 2, or 3 heteroatoms;

R^3 and R^4 are independently, halo, hydroxy, $R^{15}O(C_1-C_{12})$ alkyl, $R^{15}O(C_1-C_{12})$ alkyl, or $-OR^{15}$; or R^3 and R^4 taken together form a bidentate chelate, such as deprotonated acid or diacid group, $HOC(=O)CH_2C(=O)OH$ (malonic acid) or $HOC(=O)CH_2C(=O)OH$ (oxalic acid), or chelating group such as acid-alcohol, acid-ether, with two donor groups, or R^3 and R^4 taken together with the boron atom form a ring having the formula:



R^5 is hydrogen, halo, (C_1-C_{12}) alkyl, hydroxy (C_1-C_{12}) alkyl, halo (C_1-C_{12}) alkyl, (C_2-C_{12}) alkenyl, (C_7-C_{26}) aralkyl, (C_5-C_{13}) heteroaryl, $-OR^{15}$, $-CN$, $-NO_2$, $-CO_2R^{15}$, $-OC(O)R^{16}$, $-C(O)R^{16}$, $-NR^{13}R^{14}$, $-N(R^{23})C(O)R^{24}$, $-C(O)NR^{17}R^{18}$, $-SR^{19}$, $-SO_2R^{20}$ or $-SO_3H$; or wherein R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{23} and R^{24} are independently hydrogen, alkyl, alkenyl, (C_3-C_{12}) cycloalkyl, aryl, aralkyl or haloalkyl; each Q is a polymer chain where each chain is conjugated directly to the compound through one of R^1 , R^2 , R^5 , X^1 , X^2 or to a substituent attached to R^1 , R^2 , R^5 , X^1 , or X^2 ; and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, or 15; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R^1 and R^2 are independently phenyl, naphthyl or anthryl.
3. The compound of claim 2, wherein at least one of R^1 and R^2 is phenyl.
4. The compound of claim 2, wherein at least one of R^1 and R^2 is naphthyl.
5. The compound of claim 1, wherein at least one of R^1 and R^2 is heteroaryl.
6. The compound of claim 5, wherein at least one of R^1 and R^2 has the formula




where X^3 is O, S, or NR^a and each X^4 is independently S, or NR^a , where R^a is hydrogen, alkyl or aryl.

7. The compound of claim 6, wherein at least one of R^1 and R^2 has the formula




8. The compound of any of claims 1-7, wherein the R^1 and R^2 substituents are independently halo, hydroxy(C_1 - C_{12})alkyl, halo(C_1 - C_{12})alkyl, $R^{15}O(C_1$ - C_{12})alkyl, $R^{15}O(C_1$ - C_{12})alkyl-O-, - OR^{15} , - CO_2R^{15} , - $OC(O)R^{16}$, - $C(O)R^{16}$, - $NR^{13}R^{14}$, - $N(R^{23})C(O)R^{24}$, - $C(O)NR^{17}R^{18}$, - SR^{19} , or - SO_2R^{20} .
9. The compound of claim 8, wherein the R^1 and R^2 substituents are independently OR^{15} , or $R^{15}O(C_1$ - C_{12})alkyl-O-.
10. The compound of claim 9, wherein the R^1 and R^2 substituents are independently -Oalkyl or OH.
11. The compound of any of claims 1-10, wherein the R^3 and R^4 substituents are independently halo, hydroxy(C_1 - C_{12})alkyl, halo(C_1 - C_{12})alkyl, $R^{15}O(C_1$ - C_{12})alkyl, $R^{15}O(C_1$ - C_{12})alkyl-O-, - OR^{15} , - CO_2R^{15} , - $OC(O)R^{16}$, - $C(O)R^{16}$, - $NR^{13}R^{14}$, - $N(R^{23})C(O)R^{24}$, - $C(O)NR^{17}R^{18}$, - SR^{19} , or - SO_2R^{20} .
12. The compound of claim 11, wherein the R^3 and R^4 substituents are independently halo.
13. The compound of claim 12, wherein the R^3 and R^4 substituents are fluorine.
14. The compound of any of claims 1-13, wherein the R^3 and R^4 substituents are taken together to form a bidentate chelate.
15. The compound of claim 14 wherein the chelate is a diacid, acid-alcohol, or acid-ether group.

16. The compound of claim 15 wherein the diacid group is $\text{HOC(=O)CH}_2\text{C(=O)OH}$ or $\text{HOC(=O)CH}_2\text{C(=O)OH}$.
17. The compound of claim 14 wherein R^3 and R^4 taken together with the boron atom form a ring having the formula:




18. The compound of any of claims 1-17 wherein the polymer is attached through a group having the formula $-\text{O-R}^6-\text{O}-$ where R^6 is alkylene, alkenylene having at least two carbon atoms.
19. The compound of any of claims 1-18, wherein each Q is independently a polylactide, polyglycolide, lactide-glycolide copolymer, polyethylene glycol polylactide, polycaprolactone, polycaprolactone-polylactide block copolymers, poly(methyl methacrylate), hydroxyl propyl cellulose, polyhydroxybutyrate, polyhydroxybutyrate-valerate copolymer, polybutylene succinate, polybutylene adipate-co-terephthalate, polyethylene glycol, a sugar based polymer or a mixture thereof.
20. The compound of claim 19, wherein each Q is independently a polylactide, polyglycolide, lactide-glycolide copolymer, polyethylene glycol polylactide, polycaprolactone-polylactide block copolymers, or a mixture thereof.
21. A luminescent dye composition comprising a polymer and a compound having formula II:



wherein R^1 and R^2 are independently (C_6-C_{22}) aryl or (C_5-C_{21}) heteroaryl; R^1 and R^2 are optionally independently substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 substituent groups; where the substituent groups are halo, (C_1-C_{12}) alkyl, hydroxy (C_1-C_{12}) alkyl, halo (C_1-C_{12}) alkyl, $R^{15}O(C_1-C_{12})$ alkyl, $R^{15}O(C_1-C_{12})$ alkyl-O-, (C_2-C_{12}) alkenyl, (C_7-C_{26}) aralkyl, (C_5-C_{13}) heteroaryl, $-OR^{15}$, oxo ($>C=O$), $-CN$, $-NO_2$, $-CO_2R^{15}$, $-OC(O)R^{16}$, $-C(O)R^{16}$, $-NR^{13}R^{14}$, $-N(R^{23})C(O)R^{24}$, $-C(O)NR^{17}R^{18}$, $-SR^{19}$, $-SO_2R^{20}$, $-OSiR^{25}_3$, $-SiR^{25}_3$, $-SiR^{25}_i(OR^{25})_j$, $-P(OR^{25})_3$, $-PR^{25}_3$, isocyanate, isothiocyanate, urea, or thiourea; or two substituent groups can form a ring together with the atom to which they are attached optionally having from 3 to 8 ring atoms and optionally having 1, 2, or 3 heteroatoms; each R^{25} is independently hydrogen, alkyl or aryl; and i and j are independently integers from 1-3 wherein the sum of i and j is 3;


Y^1 is Al or B; X^1 and X^2 are independently a bond, alkyl, alkenyl, alkynyl or aryl, optionally substituted with 1, 2, 3, 4, 5, or 6 substituent groups; where the substituent groups are halo, (C_1-C_{12}) alkyl, hydroxy (C_1-C_{12}) alkyl, halo (C_1-C_{12}) alkyl, $R^{15}O(C_1-C_{12})$ alkyl, $R^{15}O(C_1-C_{12})$ alkyl-O-, (C_2-C_{12}) alkenyl, (C_7-C_{26}) aralkyl, (C_5-C_{13}) heteroaryl, $-OR^{15}$, oxo ($>C=O$), $-CN$, $-NO_2$, $-CO_2R^{15}$, $-OC(O)R^{16}$, $-C(O)R^{16}$, $-NR^{13}R^{14}$, $-N(R^{23})C(O)R^{24}$, $-C(O)NR^{17}R^{18}$, $-SR^{19}$, $-SO_2R^{20}$, $-OSiR_3$, $-SiR_3$, $-SiR^{25}_i(OR^{25})_j$, $-PR_3$, $-P(OR)_3$, isocyanate, isothiocyanate, urea, thiourea or two substituent groups can form a ring together with the atom to which they are attached optionally having from 3 to 8 ring atoms and optionally having 1, 2, or 3 heteroatoms;

R^3 and R^4 are independently, halo, hydroxy, $R^{15}O(C_1-C_{12})$ alkyl, $R^{15}O(C_1-C_{12})$ alkyl, or $-OR^{15}$; or R^3 and R^4 taken together form a bidentate chelate, such as deprotonated acid or diacid group, $HOC(=O)CH_2C(=O)OH$ (malonic acid) or $HOC(=O)CH_2C(=O)OH$ (oxalic acid), or chelating group such as acid-alcohol, acid-ether, with two donor groups, or R^3 and R^4 taken together with the boron atom form a ring having the formula:



R^5 is hydrogen, halo, (C_1-C_{12}) alkyl, hydroxy (C_1-C_{12}) alkyl, halo (C_1-C_{12}) alkyl, (C_2-C_{12}) alkenyl, (C_7-C_{26}) aralkyl, (C_5-C_{13}) heteroaryl, $-OR^{15}$, $-CN$, $-NO_2$, $-CO_2R^{15}$, $-OC(O)R^{16}$, $-C(O)R^{16}$, $-NR^{13}R^{14}$, $-N(R^{23})C(O)R^{24}$, $-C(O)NR^{17}R^{18}$, $-SR^{19}$, $-SO_2R^{20}$ or $-SO_3H$; or wherein R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{23} and R^{24} are independently hydrogen, alkyl, alkenyl, (C_3-C_{12}) cycloalkyl, aryl, aralkyl or haloalkyl; or a pharmaceutically acceptable salt thereof.

22. The composition of claim 21, wherein R^1 and R^2 are independently phenyl, naphthyl or anthryl.
23. The composition of claim 22, at least one of R^1 and R^2 is phenyl.
24. The composition of claim 22, at least one of R^1 and R^2 is naphthyl.
25. The composition of claim 21, at least one of R^1 and R^2 is heteroaryl.
26. The composition of claim 25, at least one of R^1 and R^2 has the formula




where X^3 is O, S, or NR^a and each X^4 is independently S, or NR^a , where R^a is hydrogen, alkyl or aryl.


27. The composition of any of claims 21-26, wherein the polymer is a polylactide, polyglycolide, lactide-glycolide copolymer, polyethylene glycol polylactide, polycaprolactone, polycaprolactone-polylactide block copolymers, poly(methyl methacrylate), hydroxyl propyl cellulose, polyhydroxybutyrate, polyhydroxybutyrate-valerate copolymer, polybutylene succinate, polybutylene adipate-co-terephthalate, polyethylene glycol, a sugar based polymer or a mixture thereof.

28. The composition of claim 27, wherein the polymer is a polylactide, polyglycolide, lactide-glycolide copolymer, polyethylene glycol polylactide, , polycaprolactone-polylactide block copolymers, or a mixture thereof.
29. An article prepared using a luminescent dye polymeric compound or a composition of any of claims 1-28.
30. The article of claim 29 wherein the compound of composition is a powder, film, particle, fiber, coating, gel, network, assembly, suspension or composite.
31. The article of claim 29 wherein the composition is a nanoparticle, nanofiber or nanoscale assembly.
32. The article of claim 27 which is a sensor.
33. The article of claim 32 wherein the sensor an oxygen sensor or a temperature sensor.


1/5

**Fig 1.**


2/5

**Fig. 2**


3/5

**Fig. 3**

4/5

**Fig. 4**

5/5

**Fig. 5**